Condition
Healthy Volunteers
Cardiometabolic Diseases
Locations
Not recruiting
Start date
28/03/2024
Identifiers
Trial ID
NN6022-7683,
NCT number NCT06336005,
Eudract number Not Available
NCT number NCT06336005,
Eudract number Not Available
Summary
The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases.
The aim of this study is to see if the study medicine is safe, how it works in participants body, and what the body does to the study medicine.
Participants will either get NNC6022-0001 (the new study medicine) or placebo (a "dummy medicine" without the active ingredient). Which treatment participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.
The study will last for about 10 months in total.
Trial Overview:
Treatment
DRUG: NNC6022-0001
DRUG: Placebo (NNC6022-0001)
Study type
INTERVENTIONAL
Trial duration
Mar 28 2024 - Oct 17 2024
Participants
56
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 55 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.